Trial reportClinical rheumatology2010
Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study.
Trial report in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.Health technology assessment (Winchester, England) · 2026Pooled it
- Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.European journal of clinical pharmacology · 2012Trial
- [Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].Wiener klinische Wochenschrift · 2026Article
- Rheumatoid Arthritis: A Comprehensive Review of Etiology, Pathophysiology, and Innovative Therapeutic Advancements.Current pharmaceutical design · 2026Review
- Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.European journal of clinical pharmacology · 2021Article
- Cardiovascular effects of approved drugs for rheumatoid arthritis.Nature reviews. Rheumatology · 2021Review
- Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms.Reumatologia · 2020Review
- Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future.Chinese medical journal · 2019Review
- Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis.Clinical and experimental medicine · 2018Article
- Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus.Clinical rheumatology · 2018Article
- Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.Rheumatology and therapy · 2017Review
- Update on Treatment in Cardiac Sarcoidosis.Current treatment options in cardiovascular medicine · 2017Review
- Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach.Therapeutic advances in musculoskeletal disease · 2016Article
- On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.Journal of molecular modeling · 2015Article
- Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.Arthritis research & therapy · 2011Article
- Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Open access rheumatology : research and reviews · 2010Review
- Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce. This study seeks to evaluate effectiveness and safety of leflunomide in the treatment of early RA in daily practice. This prospective, open-label, non-interventional, multi-center study was carried out over 24 weeks including adults with early RA (< or =1 year since diagnosis). Leflunomide treatment was according to label instructions. Three hundred thirty-four patients were included. Disease activity score in 28 joints (DAS28) response (reduction in DAS28 of >1.2 or reduction of >0.6 and a DAS28 of < or =5.1) was 71.9% at week 12 and 84.6% at week 24. 25.0% of patients achieved clinical remission (DAS28 < or = 2.6). Most frequently reported adverse drug reactions (ADR) were diarrhea (3.0%), nausea (2.4%), hypertension (1.8%), and headache (1.5%). Serious ADR were reported in four patients (1.2%). Leflunomide showed the effectiveness which was to be expected from controlled studies without revealing any new or hitherto unknown side effects. Onset of action was quick and significant improvement of disease was seen after 12 weeks of therapy and at even higher rates after 24 weeks irrespective of the use of a loading dose. Interestingly, the DAS28-remission rate achieved was similar to the rate seen with methotrexate or biologic therapy in other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.